Diurnal to participate in Edison “Open House”
Updated : 07:00
24 January 2022
Diurnal Group plc
("Diurnal" or the "Company")
Diurnal to participate in Edison Group's Global Healthcare "Open House" virtual conference
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will be participating at Edison Group's Global Healthcare "Open House" conference taking place virtually between 25-27 January 2022. Investors can register to attend here: https://www.edisongroup.com/event/edison-open-house-global-healthcare-2022/.
Martin Whitaker, Chief Executive Officer of Diurnal, will be presenting an overview of the Company which will be available on demand from 08:00 GMT on 25 January 2022. Martin Whitaker and Richard Bungay, Diurnal's Chief Financial Officer, will also be conducing 1x1 meetings with investors.
For further information, please visit www.diurnal.co.uk or contact: | ||
Diurnal Group plc | +44 (0)20 3727 1000 | |
Martin Whitaker, Chief Executive Officer | ||
Richard Bungay, Chief Financial Officer | ||
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Corporate Broker) | +44 (0)20 7886 2500 | |
Corporate Finance: Freddy Crossley, Emma Earl | ||
Corporate Broking: Rupert Dearden | ||
Stifel Nicolaus Europe Limited (Joint Corporate Broker) | +44 (0) 20 7710 7600 |
|
Healthcare Investment Banking: Nicholas Moore, Samira Essebiyea |
| |
Corporate Broking: Nick Adams |
| |
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 | |
Simon Conway | ||
Victoria Foster Mitchell | ||
Alex Davis |
About Diurnal Group plc:
Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.com
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.